Paradigm Biopharmaceuticals (ASX:PAR) GF Score: 28/100 (As of Jun. 30, 2026) — Near Median


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.17
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals GF Score?

Paradigm Biopharmaceuticals ASX:PAR 28 GF Score is 28 as of Jun. 30, 2026, which is 8% above its 10-year median of 26.00. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Paradigm Biopharmaceuticals has the GF Score of 28, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 3/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Paradigm Biopharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Paradigm Biopharmaceuticals  (ASX:PAR) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Paradigm Biopharmaceuticals GF Score Related Terms

ASX:PAR vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's GF Score falls into.


ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 28 mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a GF Score of 28 as of Jun. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Paradigm Biopharmaceuticals and its competitors. This is near median its historical median of 26.00. Over the past decade, Paradigm Biopharmaceuticals' GF Score has ranged from 7.00 to 39.00.
Is Paradigm Biopharmaceuticals' GF Score too high?
Paradigm Biopharmaceuticals' current GF Score of 28 is near median its 10-year median of 26.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 39.00. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' GF Score compare to VRTX and REGN?
Paradigm Biopharmaceuticals' GF Score of 28 can be compared against companies in the Biotechnology industry. Historically, Paradigm Biopharmaceuticals' own GF Score has ranged from 7.00 to 39.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current GF Score is 28, which is near median its own 10-year median of 26.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current GF Score of 28. The current GF Score is 28, which is near median its 10-year median of 26.00. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current GF Score is 28 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.17
Price